Drug Trial Radar · NCT00280059
Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy
Last checked: Nov 19, 2026Latest source record: Jan 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
660
Actual
Start
Aug 2006
Primary completion
Dec 2009
Study completion Apr 2010
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 20, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess whether Lyrica is a safe and effective treatment for partial epilepsy in comparison with an established treatment, Lamictal.
Conditions
- Epilepsy, Partial
Interventions
PregabalinDrug
dose 150-600 mg/day given BID
LamotrigineDrug
dose 100-500 mg/day given BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Seizure-free Participants (Responders) During Efficacy Assessment PhaseTime frame: Week 5 up to Week 56
Locations
102 sites in 29 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Bruges, Belgium
Pfizer Investigational Site
Brussels, Belgium
Pfizer Investigational Site
Leuven, Belgium
Pfizer Investigational Site
Plovdiv, Bulgaria
Pfizer Investigational Site
Sofia, Bulgaria
Pfizer Investigational Site
Sofia, Bulgaria
Pfizer Investigational Site
Sofia, Bulgaria
Pfizer Investigational Site
Varna, Bulgaria
Pfizer Investigational Site
Cheng Du Si Chaun, China
Pfizer Investigational Site
Chongqing, China
Pfizer Investigational Site
Tianjin, China
Pfizer Investigational Site
Xi’an, Shanxi, China
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia
Pfizer Investigational Site
Cali, Valle del Cauca Department, Colombia
Pfizer Investigational Site
Brno, Czechia
Pfizer Investigational Site
Hradec Králové, Czechia
Pfizer Investigational Site
Ostrava, Czechia
Pfizer Investigational Site
Pelhřimov, Czechia
Pfizer Investigational Site
Prague, Czechia
Pfizer Investigational Site
Rychnov nad Kněžnou, Czechia
Pfizer Investigational Site
Zlín, Czechia
Pfizer Investigational Site
Tallinn, Estonia
Pfizer Investigational Site
Tartu, Estonia
Pfizer Investigational Site
Kuopio, Finland
Pfizer Investigational Site
Tampere, Finland
Pfizer Investigational Site
Bordeaux, France
Pfizer Investigational Site
Nancy, France
Pfizer Investigational Site
Strasbourg, France
Pfizer Investigational Site
Berlin, Germany
Pfizer Investigational Site
Bonn, Germany
Pfizer Investigational Site
Essen, Germany
Pfizer Investigational Site
Frankfurt, Germany
Pfizer Investigational Site
Ulm, Germany
Pfizer Investigational Site
Ulm, Germany
Pfizer Investigational Site
Hong Kong, Hong Kong
Pfizer Investigational Site
Kowloon, Hong Kong
Pfizer Investigational Site
Shatin, Hong Kong
Pfizer Investigational Site
Budapest, Hungary
Pfizer Investigational Site
Győr, Hungary
Pfizer Investigational Site
Nyíregyháza, Hungary
Showing 40 of 102 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.